Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity

Human Pathology

Volumn 38, Issue 10, 2007, Pages 1482-1488

  Torregrossa, Liborio ^a   Faviana, Pinuccia ^a   Camacci, Tiziano ^a   Materazzi, Gabriele ^a   Berti, Piero ^a   Minuto, Michele ^a   Elisei, Rossella ^a   Vitti, Paolo ^a   Miccoli, Paolo ^a   Basolo, Fulvio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Encapsulated; Galectin 3; HBME 1; Thyroid carcinoma

Indexed keywords

GALECTIN 3;

ARTICLE; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CELL TYPE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MESOTHELIUM CELL; PAPILLARY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; THYROID CARCINOMA; TISSUE FIXATION; TISSUE SECTION;

CARCINOMA, PAPILLARY, FOLLICULAR; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548665494     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.02.013     Document Type: Article

References (37)

1. Hedinger C., Williams E.D., and Sobin L.H. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63 (1989) 908-911
2. Rosai J, Carcangiu ML, DeLellis RA. Follicular carcinoma and papillary carcinoma. In: Tumors of the thyroid gland: Atlas of tumor pathology, third series. Washington (DC): Armed Forces Institute of Pathology; 1992. pp. 49-62,65-116.
3. Rosai J., Zampi G., and Carcangiu M.L. Papillary carcinoma of the thyroid. A discussion of its several morphologic expressions, with particular emphasis on the follicular variant. Am J Surg Pathol 7 (1983) 809-817
4. Chem K.T., and Rosai J. Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am J Surg Pathol 1 (1977) 123-130
5. Baloch Z.W., and LiVolsi V.A. Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow. Expert Rev Mol Diagn 5 (2005) 573-584
6. Lloyd R.V., Erickson L.A., and Casey M.B. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28 (2004) 1336-1340
7. Hirokawa M., Carney J.A., Goellner J.R., et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26 (2002) 1508-1514
8. Rosai J. Handling of thyroid follicular patterned lesions (review). Endocr Pathol 16 (2005) 279-283
9. Williams E.D. Two proposals regarding the terminology of thyroid tumors (guest editorial). Int J Surg Pathol 8 (2000) 181-183
10. Raphael S.J. The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 13 (2002) 301-311
11. Cheung C.C., Ezzat S., Freeman J.L., et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14 (2001) 338-342
12. Bartolazzi A., Gasbarri A., Papotti M., et al. Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357 (2001) 1644-1650
13. Coli A., Bigotti G., Zucchetti F., et al. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 40 (2002) 80-87
14. Orlandi F., Saggiorato E., Pivano G., et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58 (1998) 3015-3020
15. Cvejic D., Savin S., Paunovcic I., et al. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res 18 (1998) 2637-2642
16. Herrmann M.E., LiVolsi V.A., Pasha T.L., et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 126 (2002) 710-713
17. Inohara H., Honjo Y., Yoshii T., et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85 (1999) 2475-2484
18. Van Hoeven K.H., Kovatich A.J., and Miettinen M. Immunocytochemical evaluation of HBME-1, Ca19-9 and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol 18 (1998) 93-97
19. Rossi E.D., Raffaelli M., Mulè A., et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48 (2006) 795-800
20. Mase T., Funahashi H., Koshikawa T., et al. HBME-1 immunostaining in thyroid tumours especially in follicular neoplasm. Endocr J 50 (2003) 173-177
21. Matarrese P., Fusco O., Tinari N., et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85 (2000) 545-554
22. Fernandez P.L., Merino M.J., Gomez M., et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 181 (1997) 80-86
23. Endo K., Kohnoe S., Tsujita E., et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 25 (2005) 3117-3128
24. Sheibani K., Esteban J.M., Bailey A., et al. Immunopathologic and molecular studies is an aid to the diagnosis of malignant mesothelioma. Hum Pathol 23 (1992) 107-116
25. Miettinen M., and Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumors. Virchows Arch 429 (1996) 213-219
26. Jogai S., Adesina A.O., Temmim L., et al. Follicular variant of papillary thyroid carcinoma-a cytological study. Cytopathology 15 (2004) 212-216
27. Tomada C., Kushma R., Takeuti E., et al. CD10 expression is useful in the diagnosis of follicular variant of papillary carcinoma. Thyroid 13 (2003) 291-295
28. Baloch Z.W., Abraham S., Roberts S., et al. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol 30 (1999) 1166-1171
29. Weber K.B., Kenneth R.S., Heinz D.E., et al. The use of combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122 (2004) 524-531
30. Giannini R., Faviana P., Cavinato T., et al. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 13 (2003) 765-770
31. Gasbarri A., Martegani M.P., Del Prete F., et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 17 (1999) 3494-3502
32. Mills L.J., Poller D.N., and Yiangou C. Galectin-3 is not useful in thyroid FNA. Cytopathology 16 (2005) 132-138
33. Mehrotra P., Okpokam A., Bouhaidar R., et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasm. Histopathology 45 (2004) 493-500
34. de Matos P.S., Ferreira A.P., de Oliveira Facuri F., et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47 (2005) 391-401
35. Kawachi K., Matsushita Y., Yonezawa S., et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31 (2000) 428-433
36. Jimenez R.E., Hussain M., Bianco F.J., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7 (2001) 2440-2447
37. Swanson P.E. Discordant Her-2/neu immunohistochemistry in primary and metastatic breast carcinoma. Mod Pathol 13 (2000) 47A